Researchers sought to develop a novel prognostic model for Chinese patients with relapsed diffuse large B-cell lymphoma (DLBCL) after initial R-CHOP therapy. Their findings were published in the Journal of International Medical Research.
In this retrospective study, researchers assessed characteristics and survival outcomes of 79 patients with relapsed DLBCL initially treated with R-CHOP from February 2012 to September 2016. The data was then used to develop the prognostic model, referred to as the TLLB model.
Multivariate analysis identified short time to relapse (TTR) and B symptoms as independent prognostic factors for reduced progression-free survival (PFS) and overall survival (OS). The prognostic model, developed using short TTR, lactate dehydrogenase, absolute lymphocyte count at relapse, and B symptoms as independent prognostic factors for PFS and OS, was able to separate patients into three respective risk groups with two-year PFS and OS rates of 70.7%, 40.0%, and 11.1%, and 87.5%, 53.7%, and 29.4%, respectively.
The researchers concluded that the TLLB system “provides a useful prognostic model compared with the previous TTL system.”